Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...
This report, published by Towards Healthcare, a sister firm of Precedence Research, provides an in-depth analysis of the ...
AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.
The US FDA has tightened the use of a Duchenne muscular dystrophy gene therapy after two teenage patients died from acute ...
Pharmaceutical Technology on MSN
Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal
MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...
MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to ...
The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...
Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...
MeiraGTx is cashing in on a gene therapy that restored vision to 11 children who were born legally blind, licensing the ...
Scientists discover a new gene therapy technique that may reverse ALS by restoring vital RNA signals, providing hope for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback